On December 19, 2018 Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, reported the appointment of veteran biopharma leaders Yu Liu, M.D., Ph.D., MBA, as chief medical officer and Lynne Sullivan as chief financial officer (Press release, Compass Therapeutics, DEC 19, 2018, View Source [SID1234532145]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Liu, who most recently served as vice president and head of early clinical development at Pfizer, will oversee Compass’ development of a deep pipeline of immuno-oncology and autoimmune disease candidates. The company’s lead candidate, CTX-471, a fully human monoclonal antibody that induces remodeling of the tumor microenvironment and leads to immune-mediated destruction of solid tumors, is expected to enter the clinic in the first quarter of 2019. More than 15 therapeutic candidates are advancing through preclinical development and the research team continues to generate an exciting array of novel candidates through the company’s proprietary antibody development platform.
Ms. Sullivan, who most recently served as senior vice president, finance at Biogen, will lead financial planning and management at Compass at a time of significant growth for the company.
"Yu and Lynne bring essential skills and expertise to Compass as we prepare to take our lead program into the clinic in the coming months," said Thomas Schuetz, M.D., Ph.D., the company’s co-founder and chief executive officer. "Their depth of experience and the strength of their leadership will serve us well, and we’re excited to welcome them aboard."
At Pfizer, Dr. Liu oversaw early clinical development of the company’s pipeline candidates in internal medicine, rare disease and inflammation/ immunology. Prior to Pfizer, Dr. Liu led Biogen’s early clinical development effort in rare disease, with an emphasis on cell and gene therapy. Earlier, he held various leadership roles at Bristol-Myers Squibb, culminating in his position as vice president of the oncology business unit, based in Shanghai, China. Previously Dr. Liu held positions at Essentialis Therapeutics and Amgen. Dr. Liu trained in internal medicine at Massachusetts General Hospital. He received his Ph.D. in immunology from Boston University and his MBA in finance from University of Massachusetts, Boston. He also completed a residency scholarship program in clinical research at the Harvard School of Public Health.
At Biogen, Ms. Sullivan moved through positions of increasing responsibility during her more than 10-year tenure and was named senior vice president of finance in 2015. In that role, she led financial planning and analysis, corporate finance and tax functions for Biogen’s global operations. Prior to Biogen, Ms. Sullivan served as a vice president overseeing tax function for Merck KGaA’s North American operationsand was Serono’s Vice President, Tax, Americas and International for seven years. She was a Tax Partner in the Boston office of Arthur Andersen prior to joining Serono. She currently serves as director and chair of the audit committee for both resTORbio and Solid Biosciences. Ms. Sullivan earned a bachelor’s degree in accounting from Suffolk University and a master’s in taxation from Bentley University. She is also a CPA in Massachusetts.